Immune response

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Retrieved on: 
Monday, July 26, 2021
Medical specialties, Agenus, Clinical medicine, Medicine, Cancer immunotherapy, Immunology, Vaccine, Immune response, Cancer

LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.

Key Points: 
  • LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will release its second quarter 2021 financial results before the market opens on Monday, August 9, 2021.
  • Agenus executives will host a conference call and webcast at 8:30 a.m.
  • ET the same day to discuss the results and to provide a corporate update.
  • Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

Invivoscribe Launches Grant Program to Support Novel Applications for Sequence-Based Analyses of the Immune System

Retrieved on: 
Thursday, June 24, 2021
Health, Technology, Software, Clinical trials, Pharmaceutical, Biotechnology, Immune system, Ruo, Immunology, Immune response

Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes.

Key Points: 
  • Massively parallel sequencing coupled with reagents targeting the immune receptor loci have accelerated our understanding of the immune response and immunology related disease processes.
  • Intrigued to learn what innovative applications our RUO LymphoTrack kits and services are being used for, we decided to launch this grant program to support these endeavors.
  • Successful innovative proposals submitted by applicants to our Invivoscribes Immune Biomarker Discovery grant program will receive LymphoTrack kits, controls and software to support their R&D project.
  • Additional information about the grant program and our oncology products and services can be requested by emailing [email protected] .

Imvax abstracts accepted for presentation at AACR 2021 annual meeting

Retrieved on: 
Wednesday, March 3, 2021
Branches of biology, Medical specialties, Immune system, Immunology, Growth factors, Peptide hormones, Insulin-like growth factor 1 receptor, Insulin-like growth factor 1, Antigen, Insulin-like growth factor, Immune response, Immunity

"Our team is enthused by the continued momentum of this study and the impact IGV-001 might have on those fighting GBM."

Key Points: 
  • "Our team is enthused by the continued momentum of this study and the impact IGV-001 might have on those fighting GBM."
  • The investigational treatment comprises irradiated autologous glioma cells with an antisense oligodeoxynucleotide directed at the IGF-1R (insulin-like growth factor type 1 receptor).
  • Delivered through an implantable and removable biodiffusion chamber, antigenic products are released and initiate both an innate and adaptive immune response.
  • Imvax, Inc., headquartered in Philadelphia, PA, has an exclusive license agreement with Thomas Jefferson University granting it the right to develop and market this medical technology.

Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

Retrieved on: 
Wednesday, February 10, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Branches of biology, Checkpoint inhibitor, Stimulator of interferon genes, Immune response

The novel polymer component can bind uniquely to the STING target and produce longer activation of this critical innate immune pathway.

Key Points: 
  • The novel polymer component can bind uniquely to the STING target and produce longer activation of this critical innate immune pathway.
  • The development of ONM-501 represents a new concept in STING activation that could overcome the challenges observed with earlier STING agonist compounds.
  • Preclinical studies showed that ONM501 used in combination with a checkpoint inhibitor produces an immune response effective in treating multiple cancer types.
  • OncoNano Medicine is developing a new class of products that exploit pH as a biomarker to diagnose and treat cancer with high specificity.

Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity

Retrieved on: 
Monday, February 8, 2021
Immunology, Branches of biology, T cell, Immunity, Cell-mediated immunity, Immune response, Lepromin

TNX-2100 is designed to measure T cell immunity to CoV-2.

Key Points: 
  • TNX-2100 is designed to measure T cell immunity to CoV-2.
  • There currently is no standardized laboratory test available to measure T cell immune responses to CoV-2.
  • In the planned clinical protocol for testing TNX-2100, positive skin test controls will be used to confirm that study participants have intact T cell immunity and are not immunodeficient.
  • Induration above a threshold level would signify a positive result and the diameter of the induration would indicate the amount of T cell immunity to the test peptides.

AditxtScore™ Immune Monitoring Service Will be Operational on February 1st

Retrieved on: 
Thursday, January 21, 2021
Immunology, Immune system, Immune response

Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the Company) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore Immune Monitoring Platform as of February 1st, 2021.

Key Points: 
  • Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the Company) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the operational launch of the AditxtScore Immune Monitoring Platform as of February 1st, 2021.
  • Aditxt will soon be expanding the panel to measure other components of the immune response such as cellular immunity.
  • Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.
  • The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system.

Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

Retrieved on: 
Monday, January 11, 2021
Medical specialties, Branches of biology, Medicine, Immune system, Immunology, Immunoglobulin E, Immune response, T cell, AstraZeneca, Antigen, Cancer immunotherapy, Tremelimumab

This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions.

Key Points: 
  • This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions.
  • We continue to demonstrate that specific T-cell immune receptor data can be utilized to inform the diagnosis and treatment for most diseases, said Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies.
  • We are thrilled to partner with AstraZeneca to realize the value of antigen-specific T-cell response data across their portfolio of transformative cancer medicines.
  • Adaptive will receive from AstraZeneca quarterly payments plus sequencing and data mapping fees.

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

Retrieved on: 
Friday, December 18, 2020
Medical specialties, Immunology, Medicine, Immune system, Immune response, Immunity, Adaptive immune system, Infection, Immunopathology, Autogenous vaccines

Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qus immunotherapy platform engages and trains the innate arm of the immune system that is responsible for providing the bodys first line of defense.

Key Points: 
  • Unlike traditional vaccines that direct the host adaptive immune response to a very specific antigen, Qus immunotherapy platform engages and trains the innate arm of the immune system that is responsible for providing the bodys first line of defense.
  • Optimal innate immune defenses can efficiently contain and clear infection before it spreads and plays an essential role in also directing the adaptive immune response against new infections.
  • Of note, QBKPN treatment was shown to prevent mortality from respiratory infections in aged animals, which typically have reduced innate immune competency.
  • This work will be conducted in collaboration with the NRCs Human Health Therapeutics Research Centre.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Retrieved on: 
Friday, November 6, 2020
Medical specialties, Clinical medicine, Medicine, Immune system, Pelareorep, Reoviruses, Virotherapy, Oncolytics Biotech, Cancer immunotherapy, Oncolytic virus, Immune checkpoint, Immune response

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Retrieved on: 
Friday, November 6, 2020
Medical specialties, Clinical medicine, Medicine, Immune system, Pelareorep, Reoviruses, Virotherapy, Oncolytics Biotech, Cancer immunotherapy, Oncolytic virus, Immune checkpoint, Immune response

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.

Key Points: 
  • Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus.
  • The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
  • Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents.
  • The Company does not undertake to update these forward-looking statements, except as required by applicable laws.